Active substance
Iron dextran
- SFDA 1
- US FDA 4
- US price lines 1
- NHS prices 2
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| COSMOFER 625MG-2ML AMPOULES | 312.5 mg/ml | Solution for injection/infusion · Intravenous use | 5 Ampoule | SAR 88.90 | Generic · Prescription | PHARMACOSMOS A/S | Valid |
Indications — CHI Daman Drug Formulary
ADULT ACUTE MYELOID LEUKAEMIA (AML); ANEMIA IN CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE ASSOCIATED ANEMIA; MATERNAL AND CHILD HEALTHCARE- SUPPLEMENTATION FOR MOTHER AND CHILD
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| INFED | EQ 100MG IRON/2ML (EQ 50MG IRON/ML) | injectable · injection | ALLERGAN | Prescription | 29 Apr 1974 |
| IRON DEXTRAN | EQ 50MG IRON/ML | injectable · injection | SANOFI AVENTIS US | Discontinued | 25 Apr 1957 |
| PROFERDEX | EQ 50MG IRON/ML | injectable · injection | NEW RIVER | Discontinued | 26 Mar 1981 |
| DEXFERRUM | EQ 50MG IRON/ML | injectable · injection | AM REGENT | Discontinued | 23 Feb 1996 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | INFED 100 MG/2 ML VIAL | $18.88981 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Iron dextran 100mg/2ml solution for injection ampoules | £39.85 | 5 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Iron dextran 500mg/10ml solution for injection ampoules | £79.70 | 2 ampoule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 1 Aug 2024 INFED — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - EMA PRAC 31 Oct 2019 PRAC signal: Arteriospasm coronary
Action for MAH: update of the product information: Yes - EMA PRAC 16 May 2019 PRAC signal: Arteriospasm coronary
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.